UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

__________________________________ 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): December 26, 2006

__________________________________

 

BIOVERIS CORPORATION

(Exact name of Registrant as specified in its charter)

 

 

 

 

(301) 869-9800

(Registrant’s Telephone Number, Including Area Code)

_____________________________

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 8.01 Other Events.

On December 26, 2006, BioVeris Corporation (the “Company”) announced that it entered into a Technology License Agreement with Baxter Healthcare Corporation. See the attached press release of the Company dated December 26, 2006 filed herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release dated December 26, 2006

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: December 26, 2006	BIOVERIS CORPORATION   By:/s/ George V. Migausky Name:     George V. Migausky Title:       Vice President of Finance and Chief Financial Officer

 

 

 

 

 

EXHIBIT INDEX

Exhibit 99.1

Press Release dated December 26, 2006